Proposed Information Collection Activity; FFY 2022 CCDF Discretionary Funds Reallotment (0970-0510), 9056-9057 [2022-03462]
Download as PDF
9056
Federal Register / Vol. 87, No. 33 / Thursday, February 17, 2022 / Notices
stable prices, and moderate long-term
interest rates.’’ 2 Section 10 of the FRA
authorizes the Board to ‘‘determine and
prescribe the manner in which its
obligations shall be incurred and its
disbursements and expenses allowed
and paid.’’ 3 Providing information
collected as part of the Application is
required to obtain a benefit.
Generally, information provided on
the Application may be kept
confidential from the public under
exemption 6 of the Freedom of
Information Act (FOIA) to the extent
that the disclosure of the information
‘‘would constitute a clearly unwarranted
invasion of personal privacy.’’ For
example, the release of information such
as the applicant’s address, home
telephone number, or personal email
address to the public would likely
constitute a clearly unwarranted
invasion of personal privacy and be kept
confidential. However, the release of
information such as the educational and
professional qualifications of successful
applicants would not likely constitute a
clearly unwarranted invasion of
personal privacy and may be disclosed
under the FOIA. In addition, once a
person becomes a member of the CAC,
their name, and the name and location
of the organization where they are
employed, would generally be listed on
the Board’s public website.
Current actions: On October 5, 2021,
the Board published a notice in the
Federal Register (86 FR 54977)
requesting public comment for 60 days
on the extension, without revision, of
the Application Form for Membership
on the Community Advisory Committee
Council. The comment period for this
notice expired on December 6, 2021.
The Board did not receive any
comments.
Board of Governors of the Federal Reserve
System, February 14, 2022.
Michele Taylor Fennell,
Deputy Associate Secretary of the Board.
[FR Doc. 2022–03471 Filed 2–16–22; 8:45 am]
BILLING CODE 6210–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Administration for Children and
Families
Proposed Information Collection
Activity; FFY 2022 CCDF Discretionary
Funds Reallotment (0970–0510)
Office of Child Care,
Administration for Children and
Families, HHS.
ACTION: Request for public comment.
AGENCY:
The Administration for
Children and Families (ACF), Office of
Child Care (OCC) plans to submit a
generic information collection (GenIC)
request under the following umbrella
generic: Generic Clearance for Financial
Reports used for ACF Mandatory Grant
Programs (0970–0510). This request
includes a draft announcement with
instructions to be completed by Child
Care and Development Fund (CCDF)
grant recipients that will be unable to
obligate funds that will reach the end of
their obligation period on September 30,
2022.
DATES: Comments due within 14 days of
publication. In compliance with the
requirements of the Paperwork
Reduction Act of 1995, ACF is soliciting
public comment on the specific aspects
of the information collection described
above and below.
ADDRESSES: Copies of the proposed
collection of information can be
obtained and comments may be
submitted by emailing infocollection@
acf.hhs.gov. All requests should be
identified by the title of the information
collection.
SUPPLEMENTARY INFORMATION:
Description: CCDF regulations
authorize HHS to reallot funds to other
state and tribal lead agencies that cannot
be obligated by states or tribes by the
obligation deadline. Pursuant to the
CCDF Rule (45 CFR 98.64), each year,
the state and tribal lead agency must
report to the Secretary the dollar
amount from the previous year’s grant
that it will be unable to obligate by the
end of the obligation period. Such
SUMMARY:
reports must be postmarked or emailed
by April 1. If the Secretary does not
receive a report, any funds that are not
obligated by the obligation deadline will
revert to the Federal Government.
For the purposes of this data
collection, ‘‘state’’ refers to the 50 states,
the District of Columbia, and the
Commonwealth of Puerto Rico.
The Generic Clearance for Financial
Reports used for ACF Mandatory Grant
Programs allows ACF programs to assist
in the computation of the grant awards
issued to each program’s grantees. For
more information about the umbrella
generic, see: https://www.reginfo.gov/
public/do/PRAViewDocument?ref_nbr=
202108-0970-002.
This specific GenIC will be issued as
a Program Instruction and an email
announcement on the OCC listserv.
State and tribal lead agencies that will
be unable to obligate their funds by
September 30, 2022, must inform ACF
by April 1, 2022. Lead Agencies should
submit a letter by mail or email signed
by an official authorized to make
financial decisions (e.g., Tribal Chair,
Agency Director) to their OCC Regional
Program Manager and ACF Regional
Grants Management Specialist. The
letter or email should report the amount
of funds for each of the following
funding streams that the Lead Agency
will be unable to obligate: Grant year
2021 CCDF discretionary funds, and
CCDF supplemental funds awarded
under the Additional Supplemental
Appropriations for Disaster Relief Act,
2019 (Pub. L. 116–20); the Coronavirus
Aid, Relief, and Economic Security Act
(Pub. L. 116–136); the Coronavirus
Response and Relief Supplemental
Appropriations Act (Pub. L. 116–260);
and the American Rescue Plan Act child
care stabilization funds (Pub. L. 117–2).
ACF will de-obligate funds that are
reported and re-allot those funds to state
and tribal lead agencies that request the
funds.
Respondents: Respondents will be
state and tribal officials authorized to
report on behalf of the CCDF program,
which will likely be CCDF program
administrators.
lotter on DSK11XQN23PROD with NOTICES1
ANNUAL BURDEN ESTIMATES
Title of information collection
Number of
respondents
Annual
frequency of
responses
Hourly
burden per
response
Annual hourly
burden
FFY 2022 CCDF Discretionary Funds for Reallotment ...................................
317
1
1
317
2 12
U.S.C. 225a.
VerDate Sep<11>2014
17:23 Feb 16, 2022
3 12 U.S.C. 244. This authority permits the Board
to collect personal information (e.g., bank account
Jkt 256001
PO 00000
Frm 00030
Fmt 4703
Sfmt 4703
routing numbers) needed to disburse travel funds to
CAC members.
E:\FR\FM\17FEN1.SGM
17FEN1
Federal Register / Vol. 87, No. 33 / Thursday, February 17, 2022 / Notices
Estimated Total Annual Burden
Hours: 317.
Comments: The Department
specifically requests comments on (a)
whether the proposed collection of
information is necessary for the proper
performance of the functions of the
agency, including whether the
information shall have practical utility;
(b) the accuracy of the agency’s estimate
of the burden of the proposed collection
of information; (c) the quality, utility,
and clarity of the information to be
collected; and (d) ways to minimize the
burden of the collection of information
on respondents, including through the
use of automated collection techniques
or other forms of information
technology. Consideration will be given
to comments and suggestions submitted
within 14 days of this publication.
Authority: 45 CFR 98.64.
Mary B. Jones,
ACF/OPRE Certifying Officer.
[FR Doc. 2022–03462 Filed 2–16–22; 8:45 am]
BILLING CODE 4184–55–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2019–N–0895]
Issuance of Priority Review Voucher;
Material Threat Medical
Countermeasure Product
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing the
issuance of a priority review voucher to
the sponsor of a material threat medical
countermeasure (MCM) product
application. The Federal Food, Drug,
and Cosmetic Act (FD&C Act), as
amended by the 21st Century Cures Act
(Cures Act), authorizes FDA to award
priority review vouchers to sponsors of
approved material threat MCM product
applications that meet certain criteria.
FDA is required to publish notice of the
award of the priority review voucher.
FDA has determined that SPIKEVAX
(COVID–19 Vaccine, mRNA), meets the
criteria for a material threat priority
review voucher, which has been issued
to ModernaTX, Inc., the holder of the
biologics license application.
FOR FURTHER INFORMATION CONTACT:
Myrna Hanna, Center for Biologics
Evaluation and Research, Food and
Drug Administration, 10903 New
Hampshire Ave., Bldg. 71, Rm. 7301,
lotter on DSK11XQN23PROD with NOTICES1
SUMMARY:
VerDate Sep<11>2014
17:23 Feb 16, 2022
Jkt 256001
9057
Silver Spring, MD 20993–0002, 240–
402–7911.
SUPPLEMENTARY INFORMATION: FDA is
announcing the issuance of a material
threat MCM priority review voucher to
the sponsor of an approved material
threat MCM product application. Under
section 565A of the FD&C Act (21 U.S.C.
360bbb–4a), which was added by the
Cures Act (Pub. L. 114–255), FDA will
award priority review vouchers to
sponsors of approved material threat
MCM product applications that meet
certain criteria upon approval of those
applications. FDA has determined that
SPIKEVAX (COVID–19 Vaccine,
mRNA), meets the criteria for a material
threat MCM priority review voucher.
SPIKEVAX is indicated for active
immunization to prevent coronavirus
disease 2019 (COVID–19) caused by
severe acute respiratory syndrome
coronavirus 2 (SARS–CoV–2) in
individuals 18 years of age and older.
For further information about the
material threat MCM Priority Review
Voucher Program and for a link to the
full text of section 565A of the FD&C
Act, go to https://www.fda.gov/
emergency-preparedness-and-response/
mcm-legal-regulatory-and-policyframework/mcm-relatedcounterterrorism-legislation. For further
information about SPIKEVAX, (COVID–
19 Vaccine, mRNA), go to the Center for
Biologics Evaluation and Research
Approved Vaccine Products website at
https://www.fda.gov/vaccines-bloodbiologics/vaccines/approved-vaccineproducts.
SUMMARY:
Dated: February 11, 2022.
Lauren K. Roth,
Associate Commissioner for Policy.
OMB Control Number 0910–0437—
Revision
In the Federal Register of February
21, 2020 (85 FR 10110), we published a
proposed order to reclassify certain
human immunodeficiency virus (HIV)
serological diagnostic and supplemental
tests and HIV nucleic acid (NAT)
diagnostic and supplemental tests from
class III (premarket approval) into class
II (special controls) (the proposed
order). In the proposed order, FDA
proposed special controls that the
Agency believes are necessary to
provide a reasonable assurance of safety
and effectiveness for these devices. The
proposed special controls would require
the submission of a log of all complaints
annually for a period of 5 years
following FDA clearance of a traditional
premarket notification (510(k))
submission for a device within the
scope of the proposed order.
Currently, manufacturers of HIV
serological diagnostic and supplemental
tests and HIV NAT diagnostic and
supplemental tests are subject to FDA
[FR Doc. 2022–03420 Filed 2–16–22; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2021–N–0386]
Agency Information Collection
Activities; Submission for Office of
Management and Budget Review;
Comment Request; Class II Special
Controls for Human Immunodeficiency
Virus Serological Diagnostic and
Supplemental Tests and Human
Immunodeficiency Virus Nucleic Acid
Diagnostic and Supplemental Tests
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
PO 00000
Notice.
Frm 00031
Fmt 4703
Sfmt 4703
The Food and Drug
Administration (FDA, Agency, or we) is
announcing that a proposed collection
of information has been submitted to the
Office of Management and Budget
(OMB) for review and clearance under
the Paperwork Reduction Act of 1995.
DATES: Submit written comments
(including recommendations) on the
collection of information by March 21,
2022.
ADDRESSES: To ensure that comments on
the information collection are received,
OMB recommends that written
comments be submitted to https://
www.reginfo.gov/public/do/PRAMain.
Find this particular information
collection by selecting ‘‘Currently under
Review—Open for Public Comments’’ or
by using the search function. The OMB
control number for this information
collection is 0910–0437. Also include
the FDA docket number found in
brackets in the heading of this
document.
FOR FURTHER INFORMATION CONTACT:
Domini Bean, Office of Operations,
Food and Drug Administration, Three
White Flint North, 10A–12M, 11601
Landsdown St., North Bethesda, MD
20852, 301–796–5733, PRAStaff@
fda.hhs.gov.
SUPPLEMENTARY INFORMATION: In
compliance with 44 U.S.C. 3507, FDA
has submitted the following proposed
collection of information to OMB for
review and clearance.
Medical Device Reporting—21 CFR Part
803
E:\FR\FM\17FEN1.SGM
17FEN1
Agencies
[Federal Register Volume 87, Number 33 (Thursday, February 17, 2022)]
[Notices]
[Pages 9056-9057]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-03462]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Administration for Children and Families
Proposed Information Collection Activity; FFY 2022 CCDF
Discretionary Funds Reallotment (0970-0510)
AGENCY: Office of Child Care, Administration for Children and Families,
HHS.
ACTION: Request for public comment.
-----------------------------------------------------------------------
SUMMARY: The Administration for Children and Families (ACF), Office of
Child Care (OCC) plans to submit a generic information collection
(GenIC) request under the following umbrella generic: Generic Clearance
for Financial Reports used for ACF Mandatory Grant Programs (0970-
0510). This request includes a draft announcement with instructions to
be completed by Child Care and Development Fund (CCDF) grant recipients
that will be unable to obligate funds that will reach the end of their
obligation period on September 30, 2022.
DATES: Comments due within 14 days of publication. In compliance with
the requirements of the Paperwork Reduction Act of 1995, ACF is
soliciting public comment on the specific aspects of the information
collection described above and below.
ADDRESSES: Copies of the proposed collection of information can be
obtained and comments may be submitted by emailing
[email protected]. All requests should be identified by the
title of the information collection.
SUPPLEMENTARY INFORMATION:
Description: CCDF regulations authorize HHS to reallot funds to
other state and tribal lead agencies that cannot be obligated by states
or tribes by the obligation deadline. Pursuant to the CCDF Rule (45 CFR
98.64), each year, the state and tribal lead agency must report to the
Secretary the dollar amount from the previous year's grant that it will
be unable to obligate by the end of the obligation period. Such reports
must be postmarked or emailed by April 1. If the Secretary does not
receive a report, any funds that are not obligated by the obligation
deadline will revert to the Federal Government.
For the purposes of this data collection, ``state'' refers to the
50 states, the District of Columbia, and the Commonwealth of Puerto
Rico.
The Generic Clearance for Financial Reports used for ACF Mandatory
Grant Programs allows ACF programs to assist in the computation of the
grant awards issued to each program's grantees. For more information
about the umbrella generic, see: https://www.reginfo.gov/public/do/PRAViewDocument?ref_nbr=202108-0970-002.
This specific GenIC will be issued as a Program Instruction and an
email announcement on the OCC listserv. State and tribal lead agencies
that will be unable to obligate their funds by September 30, 2022, must
inform ACF by April 1, 2022. Lead Agencies should submit a letter by
mail or email signed by an official authorized to make financial
decisions (e.g., Tribal Chair, Agency Director) to their OCC Regional
Program Manager and ACF Regional Grants Management Specialist. The
letter or email should report the amount of funds for each of the
following funding streams that the Lead Agency will be unable to
obligate: Grant year 2021 CCDF discretionary funds, and CCDF
supplemental funds awarded under the Additional Supplemental
Appropriations for Disaster Relief Act, 2019 (Pub. L. 116-20); the
Coronavirus Aid, Relief, and Economic Security Act (Pub. L. 116-136);
the Coronavirus Response and Relief Supplemental Appropriations Act
(Pub. L. 116-260); and the American Rescue Plan Act child care
stabilization funds (Pub. L. 117-2). ACF will de-obligate funds that
are reported and re-allot those funds to state and tribal lead agencies
that request the funds.
Respondents: Respondents will be state and tribal officials
authorized to report on behalf of the CCDF program, which will likely
be CCDF program administrators.
Annual Burden Estimates
----------------------------------------------------------------------------------------------------------------
Annual
Title of information collection Number of frequency of Hourly burden Annual hourly
respondents responses per response burden
----------------------------------------------------------------------------------------------------------------
FFY 2022 CCDF Discretionary Funds for 317 1 1 317
Reallotment................................
----------------------------------------------------------------------------------------------------------------
[[Page 9057]]
Estimated Total Annual Burden Hours: 317.
Comments: The Department specifically requests comments on (a)
whether the proposed collection of information is necessary for the
proper performance of the functions of the agency, including whether
the information shall have practical utility; (b) the accuracy of the
agency's estimate of the burden of the proposed collection of
information; (c) the quality, utility, and clarity of the information
to be collected; and (d) ways to minimize the burden of the collection
of information on respondents, including through the use of automated
collection techniques or other forms of information technology.
Consideration will be given to comments and suggestions submitted
within 14 days of this publication.
Authority: 45 CFR 98.64.
Mary B. Jones,
ACF/OPRE Certifying Officer.
[FR Doc. 2022-03462 Filed 2-16-22; 8:45 am]
BILLING CODE 4184-55-P